Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

AstraZeneca, Silence Therapeutics team up for siRNA drugs

by Michael McCoy
March 27, 2020 | A version of this story appeared in Volume 98, Issue 12

 

AstraZeneca will invest $80 million in cash and equity in Silence Therapeutics as part of a deal to develop small interfering RNA (siRNA) drugs for a variety of diseases. To start, London-based Silence will use its GalNAc-siRNA technology to inhibit liver-expressed gene targets. Mene Pangalos, AstraZeneca’s head of biopharmaceutical R&D, says the collaboration “adds an exciting new modality, siRNA, into our drug discovery toolbox.”

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.